News Immunocore Holdings plc

Equities

IMCR

US45258D1054

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
60.23 ^USD	+1.29%		+3.84%	-11.84%

04-29	Leerink Partners Starts Immunocore Holdings With Outperform Rating, $74 Price Target	MT
03-21	Immunocore Holdings Files Mixed-Securities Shelf Registration	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avacta Group plc - Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group	05-01	AQ
Leerink Partners Starts Immunocore Holdings With Outperform Rating, $74 Price Target	04-29	MT
Immunocore announces upcoming presentation and posters at ASCO 2024	04-24	GL
Immunocore to present at upcoming investor conferences	04-04	GL
Immunocore Holdings Files Mixed-Securities Shelf Registration	03-21	MT
Transcript : Immunocore Holdings plc Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:30 AM	03-14
Immunocore presented two posters at CROI 2024	03-05	GL
Mizuho Securities Raises Immunocore Price Target to $90 From $86, Maintains Buy Rating	03-04	MT
Immunocore to present at upcoming investor conferences	03-01	GL
Oppenheimer Adjusts Immunocore Price Target to $87 From $85, Maintains Outperform Rating	02-29	MT
Immunocore Holdings' Q4 Net Loss Narrows, Revenue Rises	02-28	MT
Transcript : Immunocore Holdings plc, Q4 2023 Earnings Call, Feb 28, 2024	02-28
Earnings Flash (IMCR) IMMUNOCORE HOLDINGS LIMITED Reports Q4 Revenue $70.2M, vs. Street Est of $68.5M	02-28	MT
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update	02-28	GL
Immunocore Holdings plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Immunocore Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Immunocore Collaborates With Bristol Myers Squibb in Advanced Cutaneous Melanoma Trial	02-22	MT
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial	02-22	GL
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024	02-21	GL
Mizuho Raises Price Target on Immunocore to $86 From $72 Ahead of Q4 2023 Earnings Announcement, Reiterates Buy Rating	02-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immunocore Holdings plc

Equities

IMCR

US45258D1054

Summary

Filters